Key result
The AngioVac system provides a nonsurgical option to debulk lead vegetations before lead removal for source control in patients with CIED-related infective endocarditis.
Case Report (n=1)
The AngioVac system provides a nonsurgical option to debulk lead vegetations before lead removal for source control in patients with CIED-related infective endocarditis.
May support feasibility of AngioVac for CIED IE in select cases; leaves open need for prospective safety and efficacy data.
Approved by the US Food and Drug Administration in 2014, the AngioVac system (AngioDynamics Inc, Latham, NY) has been used more commonly for aspiration of right-sided infective endocarditis (IE). The system requires veno-venous extracorporeal membrane oxygenation (ECMO) bypass that allows blood and debris to be suctioned from the tip of the cannula and returned to the body after filtration of the targeted material.1 For patients with a cardiac implantable electronic device (CIED)-related IE, this system provides a nonsurgical option to debulk lead vegetations before lead removal for source control.
No takes yet. Share an insight, caveat, or question.
Na et al. (2024) conducted a case report in Cardiac implantable electronic device (CIED)-related infective endocarditis in a heterotopic heart transplant (n=1). AngioVac-assisted laser lead extraction was evaluated. The AngioVac system provides a nonsurgical option to debulk lead vegetations before lead removal for source control in patients with CIED-related infective endocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: